Design and synthesis of a 1,3,6-trimethyl-1H-benzo[d]imidazole-5-sulfonamide derivative as a type I CDK8 inhibitor against colorectal cancer
- 27 November 2025
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 168, 109297
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (22377001)
- Anhui Medical University (2023xktdyxa2)
This publication has 46 references indexed in Scilit:
- Suppressing Wnt signaling of the blood‒tumor barrier to intensify drug delivery and inhibit lipogenesis of brain metastasesActa Pharmaceutica Sinica B, 2024
- Characterization of RNF43 frameshift mutations that drive Wnt ligand‐ and R‐spondin‐dependent colon cancerThe Journal of Pathology, 2022
- Targeting cell-cycle machinery in cancerCancer Cell, 2021
- Angel or Devil ? - CDK8 as the new drug targetEuropean Journal of Medicinal Chemistry, 2021
- CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitorsEuropean Journal of Medicinal Chemistry, 2019
- CDK8 Kinase Activity Promotes GlycolysisCell Reports, 2017
- CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon ResponseImmunity, 2013
- The Structure of CDK8/CycC Implicates Specificity in the CDK/Cyclin Family and Reveals Interaction with a Deep Pocket BinderJournal of Molecular Biology, 2011
- CDK8 expression in 470 colorectal cancers in relation to β‐catenin activation, other molecular alterations and patient survivalInternational Journal of Cancer, 2010
- Mastermind Recruits CycC:CDK8 to Phosphorylate the Notch ICD and Coordinate Activation with TurnoverMolecular Cell, 2004